# Shibuya Kogyo

> Shibuya Kogyo is a VC fund in Kanazawa backing Biotechnology and Health Care. See 5 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Kanazawa, Japan
- Total investments: 5
- Last investment: Mar 2021
- Lead investor: 60%
- Last updated: Aug 2026
- Website: https://www.shibuya.co.jp/

Shibuya Kogyo is a VC fund in Kanazawa focused on Biotechnology and Health Care. SHIBUYA KOGYO CO., LTD. is primarily engaged in packing plant business. The Packaging Plant segment manufactures and sells washers, sterilization machines, filling machines, capping machines, labeling machines, cargo loading machines, conveyors, carton formers and sealing machines

## Contacts

5 contacts available for Shibuya Kogyo. Shizune tracks 1 team members at Shibuya Kogyo. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/shibuya-kogyo?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 80% |
| Health Care | 3 | 60% |
| Medical | 2 | 40% |
| Beauty | 1 | 20% |
| Therapeutics | 1 | 20% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 20% |
| Series B | 1 | 20% |
| Series C | 1 | 20% |
| Funding Round | 1 | 20% |
| Convertible Note | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Japan | 4 | 80% |
| Belgium | 1 | 20% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Hirotoshi Shibuya | President and CEO | 0 | https://shizune.co/investors/profile/hirotoshi-shibuya |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Noile-Immune Biotech | Neurymune Biotech Co., Ltd. is a national cancer research center specializing in the development of cancer immunotherapies based on CAR-T cell therapy and a venture company from Yamaguchi University. They aim to be a leading company responsible for the next generation in the field of cancer immunotherapy. | $21.9M | Series C | Mar 22, 2021 |  |
| Heartseed | Heartseed is a biotechnology research firm that specializes in the development of purified ventricular cardiomyocytes derived from induced pluripotent stem cells for the treatment of heart failure. The company employs an innovative methodology that involves the creation of cardiomyocyte spheroids, small clusters of heart cells, using stem cells.These spheroids are then surgically implanted into the heart to improve its performance. | $113.4M | Seed | Jul 30, 2018 |  |
| Promethera Biosciences | Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology.Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way usingallogenic progenitor cells from healthy human livers.Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC): | $10.2M | Convertible Note | Apr 10, 2018 |  |
| Cyfuse Biomedical | Cyfuse Biomedical develops tissue fabrication systems and cell-based products in Japan and internationally. The company offers 3D BioFabrication systems and related consumables; develops and licenses 3D tissue products for therapeutic and drug development use; and engages in contract manufacturing of 3D tissue products for research purposes.Itsproducts applications include blood vessel grafts for blood access of hemodialysis patients or coronary artery bypass grafts; cardiac grafts for drug toxicology screening or supplemental therapy of myocardial infarction; cartilage grafts for plastic surgery or reconstruction; and hepatocyte grafts for drug metabolism screening or in-vivo production of clotting factors in the treatment of hemophilia.Cyfuse Biomedical was founded in 2010 and is based in Tokyo, Japan. | $12M | Series B | Mar 02, 2015 |  |
| Healios | Healios aims to commercialize the world’s first pharmaceutical hiPSC derived RPE cell transplantation for treatment of AMD in collaboration with RIKEN, one of the leading research institutes in Japan. The goal of this therapy is to promote the regeneration of retinal function and, consequently, to improve visual function in those affected withretinal degenerative diseases.The significance of the total raised capital fortifies the company’s momentum in the development of therapeutics utilizing the Nobel Prize-winning hiPSC technology and attests its uncompromising commitment to making groundbreaking strides in the field of regenerative medicine. | $425.2M |  | Oct 08, 2013 |  |

5 of 5 investments shown.

## Co-investors
- [Angel Bridge](https://shizune.co/investors/profile/angel-bridge) — VC Fund, 1 deal together
- [Astellas Venture Management](https://shizune.co/investors/profile/astellas-venture-management) — VC Fund, 1 deal together
- [BiGEN](https://shizune.co/investors/profile/bigen) — VC Fund, 1 deal together
- [Binex](https://shizune.co/investors/profile/binex-c408) — VC Fund, 1 deal together
- [Cyberdyne](https://shizune.co/investors/profile/cyberdyne) — VC Fund, 1 deal together
- [Dai-ichi Life](https://shizune.co/investors/profile/dai-ichi-life) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund
- [Limburgse Reconversie Maatschappij](https://shizune.co/investors/profile/limburgse-reconversie-maatschappij) — VC Fund
- [Qbic Fund](https://shizune.co/investors/profile/qbic-fund) — VC Fund

## Featured in investor lists
- [Biotechnology VC Funds in Belgium](https://shizune.co/investors/biotechnology-vc-funds-belgium)
- [Biotech VC Funds in Belgium](https://shizune.co/investors/biotech-vc-funds-belgium)

## FAQ

### What does Shibuya Kogyo invest in?

Shibuya Kogyo invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Series B stage. Most of the 5 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Shibuya Kogyo?

Public channels for Shibuya Kogyo include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Shibuya Kogyo?

The team at Shibuya Kogyo includes Hirotoshi Shibuya (President and CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co